Total
0
Shares
Uscom (ASX:UCM) - Executive Chairman & CEO, Rob Phillips
Executive Chairman & CEO, Rob Phillips
Sourced: Uscom
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Uscom (UCM) has been granted Russian regulatory and distribution approval for its USCOM 1A cardiac monitor after a three-year wait
  • The process was initially set to take 12 to 18 months but ended up being extended due to COVID-induced delays
  • The monitor is used to measure cardiovascular function and detect irregularities
  • Uscom Executive Chairman Professor Rob Phillips says obtaining Russia as an approved export market marks a significant addition to its network
  • Uscom shares closed the day in the grey to trade at 16.5 cents

Uscom (UCM) has been granted Russian regulatory and distribution approval for its USCOM 1A cardiac monitor after a three-year wait.

Attaining Russian Certification of Registration was expected to take 12 to 18 months, but ended up taking roughly three years for Uscom due to COVID-induced delays.

Medical devices for diagnostic or therapeutic applications are required to be registered at the central department of the Federal Service on surveillance in Healthcare and Social Development in Moscow.

Uscom said it had worked closely with its Russian distributor, Wondermed, to successfully manage the protracted regulatory process.

The USCOM 1A is the company’s non-invasive haemodynamic monitor that measures cardiovascular function, detects irregularities and can be used to guide treatment.

Uscom Executive Chairman Professor Rob Phillips said obtaining Russia as an approved export market marked a significant addition to its network.

“Uscom’s growth continues to be strong despite the pandemic and our strategy for incremental growth is simply more products, more distributors and more revenue, and we are delivering on this plan,” he said.

Uscom shares closed the day in the grey to trade at 16.5 cents.

UCM by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.